In non-randomized studies, estimation of treatment effects generally requires adjustment for imbalances in observed covariates. One such method, based on the propensity score, is useful in many applications but may be biased when the assumption of strongly ignorable treatment assignment is violated. Because it is not possible to evaluate this assumption from the data, it is advisable to assess the sensitivity of conclusions to violations of strong ignorability. Lin et al [1] have implemented this idea by investigating how an unmeasured covariate may affect the conclusions of an observational study. We extend their method to assess sensitivity of the treatment hazard ratio to hidden bias under a range of covariate distributions. We derive simple formulas for approximating the true from the apparent treatment hazard ratio estimated under a specific survival model, and assess the validity of these formulas in simulation studies. We demonstrate the method in an analysis of SEER-Medicare data on the effects of chemotherapy in elderly colon cancer patients. 
INTRODUCTION
In randomized studies, there are, on average, no systematic differences in observed or unobserved covariates between treatment arms. In observational studies, where investigators do not control treatment assignment, the treated and control groups can differ in ways that significantly affect the outcomes under study. Large differences, if not properly controlled for, can severely bias estimated treatment effects.
Traditional methods for dealing with this problem include stratification, matching, and model-based covariate adjustment. Unfortunately, these methods all have their shortcomings: Matching fails when one cannot identify subjects who match on all important covariates; this can occur even when there are only a few such covariates.
Stratification may fail when the number of strata is so large that not all strata contain both treated subjects and controls. Because the number of strata increases exponentially with the number of covariates, there is a risk of having such non-informative strata even when the number of covariates is quite small. Traditional model-based adjustment avoids these problems but depends on correct specification of the model relating the treatment and the covariates to the outcome. This can involve a perilous extrapolation if the distributions of the covariates in the comparison groups do not overlap substantially [2] .
Rosenbaum and Rubin [3] introduced a new class of methods, based on the propensity score, for dealing with these problems. The propensity score is the conditional probability of assignment to a treatment given a vector of observed covariates. If one groups the subjects into strata based on their propensity scores, then treatment and control groups within the strata are balanced with respect to these observed potential confounders. Theoretical arguments show that subclassification into five propensity
Hosted by The Berkeley Electronic Press score strata is usually adequate to remove over 90% of the bias [4] . Because exact adjustment using the propensity score will on average remove all of the bias, one can use propensity scores as a basis for matching, stratification, and regression adjustment. The method offers distinct advantages because it allows one to control for numerous covariates simultaneously by matching or stratifying on a single scalar variable [5] ; this greatly simplifies model building and estimation.
Yet no adjustment method, even propensity scores, can completely eliminate potential bias from imbalance on covariates that do not appear in the data set. Hence, it is important to investigate how variations in assumptions about unmeasured confounders may affect study conclusions. This is the role of sensitivity analysis.
In observational studies we use sensitivity analysis to investigate how biases of various magnitudes affect inferences about treatment effects [6] . We posit a parameter, call it , that measures the magnitude of the departure from a randomized experiment.
For instance, suppose that a subject who is at level 1 of an unmeasured binary confounder has times the probability of a subject who is at level 0 of being on the treatment arm. Note that sensitivity to small hidden biases does not imply that such biases are present, but that, if present, they can seriously alter conclusions.
http://biostats.bepress.com/upennbiostat/art5 Rosenbaum and Rubin [7] proposed methods for assessing the sensitivity to an unobserved binary covariate in observational studies where the outcome is binary. Lin et al. [1] extended these methods by deriving formulas to assess sensitivity to an unobserved normal covariate. Rosenbaum has also developed methods for analyzing sensitivity in matched case-control studies [8] and for matching with multiple controls [9] .
Several studies in the 1980's investigated the effect of omitted covariates and misspecification of regression models in the context of survival analysis. Gail et al. [10] showed that when important covariates are omitted, certain nonlinear regression models lead to biased treatment effect estimates in randomized experiments. However, they found that for moderately censored data, when important covariates are omitted, treatment effect estimates from exponential survival models are less biased than those obtained from Cox proportional hazards models. Similarly, Chastang et al. [11] demonstrated that the effect of omitted covariates in survival models is modest unless the covariates are strongly prognostic. Solomon [12] investigated whether the choice of model family is critical in interpreting the importance of covariates in models of survival time and concluded that treatment effect estimates are approximately proportional under the Cox model and the accelerated failure time model so that qualitative inferences are robust to misspecification. Lagakos and Schoenfeld [13] investigated the effects of misspecifying a proportional hazards regression model on the partial likelihood score test when comparing two randomized treatments and found that omitting a balanced covariate has a negligible effect on the size of the score test but there is substantial reduction in power when the covariate effect is strong. Moreover, Struthers and Kalbfleisch [14] found that ignoring one of two independent covariates results in an attenuation of the effect of the other covariate. Similarly, a study by Bretagnolle and Huber [15] [16] introduced a frailty model framework for describing the effect of omitted covariates.
Their work suggested that accelerated failure time models may be better in accounting for heterogeneity in survival times due to unobserved or omitted covariates.
In this article, we extend the methods of Lin et al. [1] by deriving simple formulas for approximating the true from the apparent treatment hazard ratio estimated from a
Weibull accelerated failure time model under a range of assumptions about the distribution of the omitted confounder. We use Monte-Carlo simulations to assess the accuracy of these approximations, and we apply our method to SEER-Medicare data to investigate the sensitivity of the treatment effect of chemotherapy on survival in elderly colon cancer patients.
STRONGLY IGNORABLE TREATMENT ASSIGNMENT
Causal inferences flow from models for the potential responses an individual could manifest under different treatments. Using the notation of Rosenbaum [17] , let r 0 represent the response that one observes if the subject receives the control treatment, and r 1 be the response that one observes if the subject receives the experimental treatment.
Because each subject receives only one treatment (z = 1 or 0), one observes r 1 for only those subjects who receive treatment (i.e., z=1), and r 0 for only those subjects who receive control. Although we can only conjecture about the causal effect of the treatment for an individual, r 1 -r 0 , we can aspire to estimate the average causal effect, which is the difference between the average responses to treatment and control in a randomly selected subject:
Treatment assignment is defined to be strongly ignorable if the response (r 0 ,r 1 ) is conditionally independent of the treatment assignment z given the observed covariates x, and the probability of receiving each treatment is positive:
For example, in the simplest randomized trial, subjects are assigned to treatment or control by the flip of a fair coin; that is
. Thus treatment assignment is strongly ignorable because the randomization probability is constant for all units regardless of the value of x. In more complicated randomized designs, randomization probabilities may depend on the values of observed covariates, but strong ignorability holds as long as these covariates are included in x.
When treatment assignment is strongly ignorable given x, we may obtain unbiased estimates of the average treatment effect, ) (
, by matched sampling on x, subclassification on x, or covariance adjustment for x. First note that if a randomly selected treatment unit (z = 1) is compared to a randomly selected control unit (z = 0), the expected difference in response is
which does not, in general, equal the average treatment effect of (2.1). Rosenbaum and
Rubin [7] demonstrated that strongly ignorable treatment assignment can lead to unbiased estimates of the average treatment effect by considering the case of simple matched sampling. In this procedure, one randomly samples a value of x from the population and then samples a treatment unit and a control from all units with this value of x. The expected difference in outcomes is then
where {} x E is the expectation with respect to the distribution of x in the population.
This does not generally equal the average treatment effect (2.1), but if we have strong
which does equal (2.1).
Rosenbaum and Rubin [7] have shown that if treatment assignment is strongly ignorable given x, then it is strongly ignorable given the propensity score, and moreover that in applications, where the exact propensity score is unknown, estimated propensity scores will serve as well. Although in observational studies we cannot directly test strong ignorability, by assessing the sensitivity of key inferences to departures from it we can determine the robustness and credibility of our conclusions.
CONFOUNDING IN THE ACCELERATED FAILURE TIME MODEL
The accelerated failure time (AFT) model provides an intuitive and flexible alternative to the Cox model in many applications [18] . In an AFT model, the covariates act multiplicatively on the time scale, implying that they affect the speed at which a subject proceeds along the time axis [19] . When the predictor is a binary indicator of assignment to a test therapy, the survival time of a treated patient is thus a multiple of the survival time of an otherwise equivalent control, and so the effect of treatment is to either slow or accelerate the passage of time. Most simply, the model is
where ) (t S T and ) (t S C are the survivor functions for subjects in the treated and control groups, respectively, and is the treatment effect. Thus values of less then 1 correspond to acceleration in the time to an event for the treated subject. The corresponding relationship between the hazard functions is
Now let Z be the treatment indicator (1 if treated, 0 if not), X a set of measured covariates, U an unmeasured confounder, and T the survival time of interest. The AFT hazard function, conditional on (Z,X,U), is
where ) ( 0 is a baseline hazard function and ) , , , ( 1 0 are regression parameters.
Here 0 and 1 are the effects of U for the control and treated groups, respectively.
Similarly, the AFT hazard function, conditional on (Z,X) only, is To completely determine an AFT model one needs to specify a probability distribution for the survival times. A common choice is the Weibull with scale parameter and shape parameter , whose baseline hazard function is
Thus the hazard in a Weibull AFT model, conditional on (Z,X,U) is
and the hazard for the reduced AFT model, conditional on (Z,X), is
In conventional notation, let )
be the conditional density function of T and
be the conditional survival function of T, and let
be the distribution function of U given Z and X. The hazard function can be written as follows:
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To determine the relationship between and * , we derive the hazard given Z and X under the full model (3.1) directly from (3.3), then match terms with the apparent hazard under the reduced model, given in (3.2). Under (3.1), the numerator in
The denominator is
Therefore, the hazard function in (3.3) can be rewritten as
Once one estimates (the shape parameter of the Weibull distribution) and specifies the distribution of U, one can use (3.4) to determine an explicit formula for the hazard function. In section 3.1, we derive an explicit formula for the hazard function assuming that the unknown confounder follows a Gamma distribution. In sections 3.2, 3.3 and 3.4, we present similar formulas for normal, binomial and Poisson confounders.
Derivations appear in the Appendix.
Unknown Gamma Confounder
Assume that, conditional on Z and X, the confounder U is Gamma with shape X , Z and scale X , Z . We rewrite the hazard in (3.4) as follows: If the events are rare then t is small and the hazard simplifies to In (3.5), 0 and 1 are the effects of U for the control and treated groups, respectively. Furthermore, 0 and 1 are the shape parameters of U, and 0 and 1 the scale parameters of U, for the control and treated groups, respectively. We can now estimate the true treatment effect by first estimating the apparent treatment effect * from observed data and then applying (3.5) . This formula also proves that when the sensitivity parameters are fixed, the variance of ˆi s the same as that of * , which allows us to easily calculate a confidence interval for .
Unknown Normal Confounder
Now suppose that, conditional on Z and X, the unknown confounder U is normally distributed with mean µ are the means of U for the control and treated groups, respectively.
Unknown Binary Confounder
Assume that U is binary with success probability
. If U is independent of X conditional on Z, which implies that
does not depend on X, the treatment effect is 
Unknown Poisson Confounder
Next suppose that, conditional on Z and X, U is Poisson with mean x , z 1 . As before, if events are rare and U is conditionally independent of X given Z so that
Here 0 1 and 1 1 are the means of U for the control and treated groups, respectively.
SIMULATIONS
In the previous section, we developed formulas to estimate in the presence of an unmeasured confounder with a specified distribution (gamma, normal, binomial, or Poisson) assuming an AFT model. We now assess the accuracy of these approximations by Monte Carlo. We generated survival times under the AFT model from We set 30% of the subjects to be in the treated group (Z = 1) and 70% in the control group (Z = 0) and assumed that X was normal with mean 1 for the treated group, mean 0 for the control group, and variance 1 for both groups. We generated censoring times from the Uniform (0,2) distribution where 2 was chosen to fix the censoring rate.
Results corresponding to the four models appear in tables 1 through 4. In each simulation, there were 1000 samples, each containing 1000 subjects. With binary U, our results suggest that (3.7) is a good approximation under a wide range of censoring rates. When U is normal, however, the approximation (3.6) is adequate only when the censoring rate is over 90% or when the effect of the unmeasured confounder on survival time is small ( 75 . 0 < ). When U is Poisson, the approximation (3.8) is satisfactory when the censoring percentage is over 75%. Finally, when U has a gamma distribution, (3.5) is a good approximation when the censoring rate is over 50% or when the effect of U on T is small ( 25 . 0 < ). Overall, if the censoring rate is high or the effect of U on T is small, then the approximations are sufficiently unbiased for practical purposes.
COLON CANCER STUDY
The aim was to estimate the effect of adjuvant chemotherapy with 5-flourouracil (5FU) in extending survival in older, node-positive colon cancer patients. Our data source was the Surveillance Epidemiology and End Results -Medicare (SEER-Medicare)
database that links cancer registry information with Medicare claims data [20] . SEER collects information on tumor location, stage of disease, and demographics (e.g. age, race, sex, and area of residence), together with primary surgical and radiation treatment and survival; it covers roughly 14% of the US population. The linked Medicare files contain extensive diagnostic, treatment, and cost data.
We identified all individuals in the database who had a first primary diagnosis of We hypothesized that 5FU treatment would be associated with longer survival, but we were concerned that the subjects receiving 5FU would be quite different from the others in terms of covariates that are likely to predict survival. Of a total of 4,768 patients in the dataset, 2,479 received 5FU and 2,289 did not. An initial analysis showed significant differences in several background covariates (Table 5 ). Note, for example, that younger, urban and white patients were all more likely to be treated.
We estimated propensity scores from a logistic regression including 22 potential predictors. A patient's propensity score is his estimated probability of being treated with 5FU given his background covariates. We assigned patients to five strata based on quintiles of the distribution of the propensity scores. Patients in the first quintile have the lowest propensity scores, indicating that they were the types of patients who were less likely to receive 5FU (although some did). Those assigned to each successive quintile were more likely to receive 5FU (although in each case some did not).
We compared treated and control groups on each of the 22 covariates using a twoway ANOVA with propensity quintile and treatment group (5FU/no 5FU) as the factors.
As expected, the two groups were quite similar within quintiles.
We estimated the effect of treatment on survival separately within each quintile (Table 6 ). For instance, in quintile 1, the hazard of death for those who received 5FU is about 81% of the hazard for those who did not receive 5FU. Each of the five hazard ratios is less than 1, suggesting that 5FU improves survival. All ratios are significant except for quintile 1, which is the stratum least likely to receive 5FU.
Next we estimated the treatment effect by an AFT model that included the propensity score quintile (to account for the initial imbalance in the measured covariates) and age at diagnosis, which was not perfectly balanced even after propensity score adjustment. Our results show that the hazard of death for those who received 5FU is about 66% of the hazard for those who did not.
Although the propensity score adjustment included 22 covariates, which presumably captured most of the potential confounding, the possibility still exists that the apparent association between treatment and response resulted from some unknown or unmeasured covariates that were associated with both treatment and outcome. An example of a binary unmeasured confounder in the 5FU study is performance status or functional impairment. Performance status has been linked to survival in cancer patients and is likely to be associated with the decision to treat with chemotherapy (i.e., the better the status, the more likely a patient is to receive chemotherapy). Thus it is possible that decreased performance status is unequally distributed between the treatments, such that its prevalence was higher in the group not treated with 5FU, and that it is associated with an increased hazard of death. This could bias even the propensity-score adjusted analysis. Our methodology allows us to model this in a formal sensitivity analysis.
We estimated the hazard ratio for 5FU treatment to be 0.66 with a 95% confidence interval of (0.60, 0.73). We assumed in our sensitivity analysis that the unmeasured confounder is more prevalent in the group not treated with 5FU and that it is associated with decreased survival, which would bias results toward the null. Important parameters in the sensitivity analysis include the prevalence of the unknown confounder in the treated and control groups in addition to the relative hazard of death associated with the unmeasured confounder.
Our analyses (Table 7) show that a binary confounder would need to increase the risk of death by at least 50% (hazard of at least 1.5) before it would alter our results.
Moreover, a confounder with a hazard ratio of 1.5 or greater would have to be significantly unbalanced between groups to alter results. For example, a confounder with a hazard of 1.75 would need to be more than 5 times as prevalent in the control group to render the treatment effect non-significant. Thus the beneficial effect of 5FU appears to be robust to departures from strong ignorability.
DISCUSSION
We have demonstrated a methodology for assessing sensitivity of inferences to departures from strong ignorability of treatment assignment, within the context of the accelerated failure time model for survival. The adjustments are simple to compute, in that they merely require one to fit the AFT model without the confounder, then specify the parameters of the confounding process and do a simple linear adjustment. The range of validity of the approximations depends on the model for the confounder, but all are valid as long as the fraction of events is small and the effect of the confounder is modest.
The latter is a less important issue because we are generally more interested in precise quantitation of sensitivity to small departures from the strongly ignorable model. The assumption of rare events in the proposed model is not a serious limitation because one of the main reasons that observational studies are conducted is precisely because the event of interest is rare. Moreover, our simulations suggest that in the case of unmeasured binary confounders, the approximations are adequate even when the fraction of events is not small. When the approximation is suspect, one can develop adjustments by straightforward simulation approaches. Although we have applied our method in the context of a propensity score analysis, the adjustment formulas apply equally well to an AFT model estimated in the context of a matched, stratified or purely model-based analysis.
Our example demonstrates a practical application of the method in a study of survival of older colon cancer patients. Our analysis posited that an underlying binary performance status variable, which was not explicitly coded in the dataset, could have influenced the decision to administer adjuvant chemotherapy and been predictive of outcome. In other applications, where such a rich array of covariates was not available, one might hypothesize that the candidate confounder was some count variable (modeled with the Poisson), a symmetric continuous variable (modeled with the normal), or a skewed continuous variable (modeled with the gamma). We have derived adjustment formulas for each of these situations.
APPENDIX

Unknown Binary Confounder
Assume that the unknown confounder U is binary with success probability
If events are rare, implying that t is small, the approximate hazard is
For simplicity, assume that U is independent of X conditional on Z, which implies that
does not depend on X. Thus letting As before, if events are rare, then t is small and the formula for the hazard will simplify. We also assume that U is conditionally independent of X given Z so that 
